Opinion|Videos|February 17, 2025
Considerations for Switching Systemic Agents in Atopic Dermatitis
Panelists discuss the prevalence of treatment-refractory moderate to severe atopic dermatitis, noting factors such as intolerance or inability to use high-potency topical agents as common reasons for treatment failure, and emphasize the importance of considering alternative agents or switching treatments when necessary, particularly in pediatric patients, with biologics and Janus kinase (JAK) inhibitors being key options as evidenced by studies such as Blauvelt 2023, Keow & Abu-Hilal 2024 , and JADE EXTEND.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How prevalent is treatment-refractory moderate to severe atopic dermatitis?
- What are other reasons for treatment failure (eg, intolerance, inability to use high-potency topical agents)?
- When do you consider adding or switching agents?
- What other treatment options exist for pediatric atopic dermatitis?
- How do you determine which treatment to switch to?
- Biologic to JAK inhibitor: Blauvelt 2023, Keow & Abu-Hilal 2024, JADE EXTEND, Shi 2022
Advertisement
Related to this article
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.
In 5.2 million US infants, newborn vitamin K nonreceipt rose to 6.8% by 2025 and was tied to a 47% higher bleeding risk by 6 months.
New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.
Jessica Nash, MD, IBCLC, shares strategies for assessing breastfeeding, identifying latch problems, and connecting families with lactation resources.
Find out the 4 FDA decisions to watch in November 2026 for pediatric care.
Michael Pistiner, MD, discusses how pediatricians can support food allergy management in schools through accurate diagnosis, emergency plans, and education.
Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Skipping newborn vitamin K tied to 47% higher infant bleeding risk
2
Breastfeeding essentials: Assessing latch and milk transfer
3
Maternal RSVpreF 78% effective against infant RSV hospitalization
4
Study identifies gaps in infant RSV immunization timing
5